You have 9 free searches left this month | for more free features.

bevacizumab

Showing 1 - 25 of 1,255

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Bevacizumab
  • +2 more
  • Los Angeles, California
  • +17 more
Jan 27, 2023

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 13, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

Withdrawn
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
Jun 1, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
Feb 26, 2023

Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,

Recruiting
  • Cervical Adenocarcinoma
  • +47 more
  • Bevacizumab
  • +3 more
  • Phoenix, Arizona
  • +3 more
Dec 5, 2022

Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

Recruiting
  • Locally Advanced Lung Non-Small Cell Carcinoma
  • +9 more
  • Duarte, California
  • +4 more
Aug 17, 2022

Colorectal Cancer Metastatic Trial in Guangzhou (Dexamethasone, Anisodamine, Oxaliplatin)

Recruiting
  • Colorectal Cancer Metastatic
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 3, 2023

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma

Active, not recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +7 more
  • Anetumab Ravtansine
  • +2 more
  • Orange, California
  • +22 more
Oct 22, 2022

Colorectal Cancer Trial (ME-344, Bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Apr 20, 2023

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Mirvetuximab soravtansine plus Bevacizumab
  • Bevacizumab
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma Trial in Houston (biological, drug, other)

Active, not recruiting
  • Invasive Breast Carcinoma
  • Triple-Negative Breast Carcinoma
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 18, 2022

Glioblastoma Trial in Boston, New York, Philadelphia (Pembrolizumab, Bevacizumab, Re-irradiation)

Active, not recruiting
  • Glioblastoma
  • Boston, Massachusetts
  • +4 more
Dec 7, 2022

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma

Not yet recruiting
  • Metastatic Colon Adenocarcinoma
  • +6 more
  • Balstilimab
  • +10 more
  • Duarte, California
    City of Hope Medical Center
Nov 17, 2022

Glioblastoma Multiforme, Anaplastic Astrocytoma Trial in New York (Bevacizumab)

Recruiting
  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Bevacizumab
  • New York, New York
    Lenox Hill Brain Tumor Center
Nov 10, 2022

Glioma Trial in Madison (Bevacizumab, PRDR)

Recruiting
  • Glioma
  • Bevacizumab
  • PRDR
  • Madison, Wisconsin
    University of Wisconsin Hospital and Clinics
Nov 14, 2022

Glioma, Recurrent Glioma Trial in Shanghai (Hypofractionated Stereotactic Radiotherapy, Bevacizumab)

Active, not recruiting
  • Glioma
  • Recurrent Glioma
  • Hypofractionated Stereotactic Radiotherapy
  • Bevacizumab
  • Shanghai, Shanghai, China
    CyberKnife Center, Department of Neurosurgery, Huashan Hospital
Nov 3, 2022

Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer Trial in United States

Recruiting
  • Combined Hepatocellular Carcinoma and Cholangiocarcinoma
  • +2 more
  • Atezolizumab
  • +6 more
  • Auburn, California
  • +16 more
Aug 17, 2022

Hepatocellular Carcinoma Trial (NP137, Atezolizumab, Bevacizumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Sep 23, 2022

Multimodal Deep Learning Radiomic Nomogram for Evaluation of

Not yet recruiting
  • Colorectal Cancer
  • Liver Metastases
  • Bevacizumab
  • Shanghai, Shanghai, China
    Zhongshan hospital
Jan 4, 2023

Solid Tumors Trial run by the National Cancer Institute (NCI) (Bevacizumab, Dasatinib)

Completed
  • Solid Tumors
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 19, 2023

Recurrent Glioblastoma Trial in United States (Bevacizumab, Cediranib, Cediranib Maleate)

Active, not recruiting
  • Recurrent Glioblastoma
  • Bevacizumab
  • +3 more
  • La Jolla, California
  • +26 more
Jun 28, 2022

Hepatocellular Carcinoma Trial (Ezurpimtrostat, Atezolizumab, Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Grenoble, France
    University Hospital
Dec 23, 2022

Carcinoma, Ovarian Epithelial Trial in Hidaka (pembrolizumab, olaparib, bevacizumab)

Recruiting
  • Carcinoma, Ovarian Epithelial
  • pembrolizumab
  • +5 more
  • Hidaka, Saitama, Japan
    Saitama Medical Uiversity International Medical Center
Apr 25, 2022

Colorectal Cancer Metastatic Trial in Vejle (drug, dietary supplement, other)

Recruiting
  • Colorectal Cancer Metastatic
  • Vejle, Denmark
    Department of Oncology, Vejle Hospital
Nov 17, 2022